Free shipping on all orders over $ 500

PT2399

Cat. No. M10501

All AbMole products are for research use only, cannot be used for human consumption.

PT2399 Structure
Synonym:

PT-2399

Size Price Availability Quantity
5mg USD 280  USD280 In stock
10mg USD 440  USD440 In stock
25mg USD 780  USD780 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

PT2399 is a potent and orally available antagonist of HIF-2 with an IC50 of 6 nM, PT2399 selectively disrupts the heterodimerization of HIF-2α with HIF-1β. PT2399 dissociates HIF-2 (an obligatory heterodimer [HIF-2α/HIF-1β])14 in human Clear cell Renal Cell Carcinoma (ccRCC) suppressing tumorigenesis in 56% (10/18) lines. PT2399 (20 μM) causes off-target toxicity because it inhibits the proliferation of HIF-2α −/− 786-O cells and other cancer cell lines with undetectable HIF-2α. PT2399 (0.2-2 μM; 0-21 days) inhibits 786-O cells soft agar growth.

PT2399 reduces tumor cell density and increases fibrosis in RCC bearing mice. PT2399 (100 mg/kg; oral gavage; every 12 hours) is more active than SU 11248, and inhibits tumor growth in several SU 11248-resistant tumors in RCC bearing mice.

Protocol (for reference only)
Cell Experiment
Cell lines 786-O cells
Preparation method PT2399 inhibited 786-O cell soft agar growth at 0.2-2 μM.
Concentrations 0 μM, 0.2 μM, 2 μM
Incubation time 0-21 days
Animal Experiment
Animal models Mice with RCC tumorgraft
Formulation in 10% EtOH, 30% PEG400, 60% MCT
Dosages 100 mg/kg
Administration oral gavage every 12 hours
Chemical Information
Molecular Weight 419.32
Formula C17H10F5NO4S
CAS Number 1672662-14-4
Solubility (25°C) DMSO 90 mg/mL
Storage -20°C, sealed
References

[1] Paul M Wehn, et al. J Med Chem. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)

[2] Olga Martinez-Saez, et al. Crit Rev Oncol Hematol. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy

[3] Wenfang Chen, et al. Nature. Targeting renal cell carcinoma with a HIF-2 antagonist

[4] Hyejin Cho, et al. Nature. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Related HIF Products
HIF-1α-IN-3 

HIF-1α-IN-3 is a hypoxia-selective HIF-1α inhibitor.

HIF-2α-IN-2 

HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor, has an IC50 of 16 nM in scintillation proximity assay (SPA).

PRLX-93936 dihydrochloride 

PRLX-93936 dihydrochloride is a HIF-1α inhibitor with anticancer activity.

3-Aminobenzoic acid

3-Aminobenzoic acid is a hypoxia-inducible factor-1α (HIF-1α) inhibitor.

Steppogenin

Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: PT2399, PT-2399 supplier, HIF, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.